Skip to content

Ultragenyx Pharmaceutical

US · RARE #3012 by market cap Listed 1970
16.48 -0.74 -4.30%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:31

Price chart

Pre-market 16.88 -1.97%
After-hours 16.50 +0.12%
Overnight 17.18 -0.23%
35.8712.8816.482026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on RARE?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -41.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 24.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 83.8% Better than 93%
Operating margin -79.5% Better than 8%
Net margin -85.4% Better than 7%
Return on equity -656.0% Better than 1%
Return on invested capital -435.1% Better than 0%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -36.2% Better than 13%
6-month return -29.5% Better than 19%
12-month return (ex latest month) -53.4% Better than 2%
Distance below 52-week high 58.7% Better than 12%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.5x Better than 66%
Debt to assets 2.3% Better than 87%
Interest coverage -8.2x Better than 14%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 47.4% Better than 26%
Upside to average target 54.1% Better than 69%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +2.49%
1M +2.87%
3M -34.91%
6M -29.48%
YTD -28.35%
1Y -47.15%
3Y -58.12%
5Y -79.22%

Key statistics

Price & volume

Prev close
17.22
Open
16.94
Day range
16.43 - 17.35
Avg price
16.62
Volume
3.01M
Turnover
50.02M
Amplitude
5.37%
52-week range
12.73 - 39.89

Valuation

P/E
-2.83
P/E (TTM)
-3.19
P/B
-4.47
EPS
-5.83
Net profit
-594.22M
Net assets
-376.00M

Share structure

Market cap
1.68B
Float cap
1.38B
Shares out
101.92M
Float shares
83.54M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 14% of range
12.73 39.89

58.7% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-2.06M net over the window

Short interest

Shares short
23.62M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Ultragenyx Pharmaceutical (RARE)?

Ultragenyx Pharmaceutical last traded at 16.48. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Ultragenyx Pharmaceutical's market cap?

About 1.68B.

What is the P/E ratio of Ultragenyx Pharmaceutical?

The trailing twelve-month P/E is -3.19. The Valuation tab shows it against the stock's own five-year range.

Does Ultragenyx Pharmaceutical pay a dividend?

Ultragenyx Pharmaceutical does not currently pay a regular dividend.

Is Ultragenyx Pharmaceutical a buy according to analysts?

The consensus of 19 analysts is a Buy rating, with an average 12-month price target of 25.39, which implies 54.1% upside from the current price. This is not investment advice.

What is Ultragenyx Pharmaceutical's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Ultragenyx Pharmaceutical a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:31:44 · For reference only, not investment advice and not tailored to your situation.

Ultragenyx Pharmaceutical discussion 0 comments

Add a comment